EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally
Boomi™, the intelligent connectivity and automation leader, today announced that leading UK-based technology distributor EXERTIS is expanding its use of Boomi’s category-leading, unified integration platform to improve partner and customer satisfaction on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808691045/en/
EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally (Graphic: Business Wire)
EXERTIS works with 2,400 technology partners, including Apple, Samsung, Microsoft, and Dell Technologies, and serves more than 50,000 retailers and resellers in 20+ countries. As part of a full spectrum of services, EXERTIS supplies IT hardware and software to electronic retailers and hosts some clients’ ecommerce stores, managing their full, end-to-end customer journeys.
Prior to using Boomi, EXERTIS had grown through acquisition, where each of its operating entities possessed a mix of legacy and modern integration tools. As a result, manual custom coding; ageing, on-premises enterprise service bus (ESB) systems; and outdated electronic data interchange (EDI) tools and services were widespread and disconnected. This led to slow development and deployment of new integrations, high technical debt, and a declining pool of developers with specialised skills that stifled the scalability and flexibility EXERTIS needed.
With an acquisition strategy that benefitted from inter-company trade synergies, EXERTIS needed a future-proof solution. After evaluating various integration and EDI solutions, EXERTIS saw how Boomi could modernise its IT environment and support its growth and acquisition strategy through the platform’s low-code ease of use; speed of development; and multiple capabilities in a unified, multi-tenant, cloud-based solution.
Using its core integration, B2B/EDI management, and API management capabilities, the Boomi platform enables EXERTIS to connect into over 100 internal and third-party systems with 200 more systems in the pipeline, providing EXERTIS with the agility for further innovation.
“EXERTIS has its origins in venture capitalism and private equity, and a core part of our work centred around the integration of acquired entities,” said Tim Griffin, CEO, EXERTIS. “There are lots of solutions on the market, but I would put Boomi at the top, especially when you consider its multi-tenant architecture and cloud basis. Our developers became proficient in as little as three weeks, and we now have a shared development environment that promotes reuse of integrations across our business.”
In light of its early success, EXERTIS is expanding its use of Boomi to digitally transform its global environment for integration and EDI transactions, and improve partner and customer satisfaction on a global scale.
“We’re delighted to expand our engagement and support of EXERTIS as they continue to grow globally,” said Adrian Trickett, Vice President and General Manager, EMEA at Boomi. “By enabling frictionless transactions, EXERTIS has increased the percentage of orders from its partners and customers, and freed time for its people to pursue more value-adding work.”
Learn more about the EXERTIS use case with Boomi here.
Additional Resources
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organisations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808691045/en/
Contact information
Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom